Thoracic and Gastrointestinal Oncology Branch Medical Clinical Core

医用TGIB有一个强大的临床计划，用于治疗标准治疗失败的晚期胸癌和胃肠道癌症患者。胸科研究小组正在对肺癌、恶性间皮瘤和胸腺癌患者进行创新研究。这些措施包括使用NCI的科学家开发的新疗法。我们团队的一个主要关注点是针对肿瘤抗原的药物的开发，间皮蛋白在许多癌症中高度表达。我们正在使用一种单抗-MORAb-009，一种免疫毒素-SS1P，一种抗体药物结合物-BAY 94-9343和一种间硫蛋白疫苗-CRS-207治疗这些癌症。此外，我们正在进行临床试验，使用免疫疗法药物来治疗标准治疗失败的胸癌患者。TGIB还在进行胃肠道癌症的治疗研究，特别是肝癌。TGIB内的研究人员已经建立了一个强有力的计划来治疗肝癌患者，包括单独使用免疫治疗药物或与放射治疗联合使用。胃肠道小组还在进行治疗胰腺癌的新药的临床试验。

The medical TGIB has a robust clinical program for treatment of patients with advanced thoracic and GI cancers who have failed standard therapies. The thoracic team is conducting innovative studies for patients with lung cancer, malignant mesothelioma and thymic cancers. These include use of novel treatments developed by scientists at the NCI. A major focus of our team is the development of drugs targeting the tumor antigen, mesothelin that is highly expressed in many cancers. We are using a monoclonal antibody- MORAb-009, an immunotoxin -SS1P, an antibody drug conjugate- BAY 94-9343 and a mesothelin vaccine- CRS-207 to treat these cancers. In addition, we are conducting clinical trials using immunotherapy agents to treat patients with thoracic cancers who have failed standard treatments. The TGIB is also conducting studies for treatment of gastrointestinal cancers with a special emphasis on liver cancer. Investigators within the TGIB have established a robust program for treatment of patients with liver cancer including use of immunotherapy agents either alone or in combination with radiation therapy. The gastrointestinal group is also conducting clinical trials of novel agents for treatment of pancreatic cancer.